Trial Profile

A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2025 Number of treatment arms has been changed from 4 to 3.
06 Mar 2024 Results assessing ascending single doses (trial A) and ascending multiple doses (trial B) of MK-8527 in adults (aged 18-55 years) without HIV assessing safety and pharmacokinetics, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
06 Mar 2024 Results (n=31) of pooled data from NCT03615183 and NCT05494736 assessing the antiretroviral activity of MK-8527 in treatment-naive participants with HIV-1 for the 1-mg dose group presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com